Find your next paid study

Emory UniversityNCT05741164

Recurrent Mantle Cell LymphomaRefractory Mantle Cell Lymphoma

A Phase 1/2 Study of the CELMoD Agent Golcadomide in Combination With Rituximab in Patients With Relapsed or Refractory Mantle Cell Lymphoma

This phase I/II trial tests the safety, side effects, best dose and effectiveness of golcadomide in combination with rituximab in treating patients with mantle…

City of Hope Medical CenterNCT07578077

Osteosarcoma RecurrentOsteosarcoma in ChildrenRelapsed Osteosarcoma+1 more

Study of Tegavivint, a Transducin Beta-like Protein 1 (TBL1) Inhibitor, With Gemcitabine in Patients With Relapsed or Refractory Osteosarcoma

The goal of this clinical trial is to define the maximum tolerated dose (MTD) and/or Recommended phase 2 dose (RP2D) of Tegavivint in combination with Gemcitab…

Emory UniversityNCT07144254

Accelerated Phase Chronic Myelogenous Leukemia, BCR-ABL1 PositiveAcute Lymphoblastic LeukemiaBCR-ABL1 Fusion Protein Expression+5 more

Phase II Study of the Combination of Blinatumomab and Ponatinib in Patients With Philadelphia Chromosome (Ph)-Positive and/or BCR-ABL Positive Acute Lymphoblastic Leukemia (ALL)

This phase II trial studies how well blinatumomab, methotrexate, cytarabine, and ponatinib work in treating patients with Philadelphia chromosome (Ph)-positive…

M.D. Anderson Cancer CenterNCT03263572

Blasts 10-19 Percent of Bone Marrow Nucleated CellsBlasts More Than 5 Percent of Bone Marrow Nucleated CellsHigh Risk Chronic Myelomonocytic Leukemia+4 more

Phase 1 Dose Escalation Study of CPX-351 for Patients With Int-2 or High Risk IPSS Myelodysplastic Syndromes and Chronic Myelomonocytic Leukemia After Failure to Hypomethylating Agents

This phase I trial studies best dose and side effects of liposome-encapsulated daunorubicin-cytarabine (CPX-351) and how well it works in treating patients wit…

M.D. Anderson Cancer CenterNCT03896269

Advanced Endometrial CarcinomaAdvanced Head and Neck Squamous Cell CarcinomaAdvanced Malignant Solid Neoplasm+35 more

A Phase 1 Open-Label, Dose-Escalation and Dose-Expansion Study to Investigate the Safety, Pharmacokinetics, and Anti-Tumor Activity of IACS-6274 as Monotherapy and in Combination in Patients With Advanced Solid Tumors

To find the highest tolerable dose of IACS-6274 that can be given alone, in combination with bevacizumab and paclitaxel, or in combination with capivasertib to…

Recurrent B-Cell Non-Hodgkin LymphomaRecurrent Diffuse Large B-Cell LymphomaRecurrent Follicular Lymphoma+5 more

A Pilot Study of Loncastuximab Tesirine in Specific Populations of Relapsed/Refractory B-Cell Malignancies

This phase II trial tests whether loncastuximab tesirine works to shrink tumors in patients with B-cell malignancies that have come back (relapsed) or does not…

University of WashingtonNCT05453396

Lymphoma, Non-HodgkinRelapsed Diffuse Large B Cell LymphomaRefractory Diffuse Large B-cell Lymphoma+2 more

Phase IIa Trial to Evaluate Epcoritamab Administered Before and After CAR-T Cell Therapy in Patients With Relapsed or Refractory Large B-cell Lymphomas

This study investigates the feasibility and efficacy of epcoritamab treatment before CAR T cells. This study also investigates if, when patients have residual …

Abramson Cancer Center at Penn MedicineNCT06458439

Chronic Myelomonocytic LeukemiaMyelodysplastic SyndromeRecurrent Chronic Myelomonocytic Leukemia+3 more

A Phase II, Open-Label, Study of Subcutaneous Canakinumab, an Anti-IL-1β Human Monoclonal Antibody, for Patients With Low or Int-1 Risk IPSS/IPSS-R Myelodysplastic Syndromes and Chronic Myelomonocytic Leukemia

This phase II trial studies how well canakinumab works for the treatment of low- or intermediate-risk myelodysplastic syndrome or chronic myelomonocytic leukem…

M.D. Anderson Cancer CenterNCT04239157

Advanced CholangiocarcinomaAdvanced Hepatocellular CarcinomaAdvanced Malignant Solid Neoplasm+4 more

First in Human Dose Escalation Study of AU409 in Patients With Advanced Primary Liver Cancers or Advanced Solid Tumor With Liver Predominant Metastatic Disease

This phase I trial tests the safety, side effects, and best dose of a new intervention, AU409, in treating patients with primary liver cancers that may have sp…

University of Southern CaliforniaNCT05791448

Juvenile Myelomonocytic LeukemiaRecurrent Acute Biphenotypic LeukemiaRecurrent Acute Undifferentiated Leukemia+26 more

Phase I Study of Adoptive Immunotherapy With CD8+ and CD4+ Memory T Cells Transduced to Express an HA-1-Specific T Cell Receptor (TCR) for Children and Adults With Recurrent Acute Leukemia After Allogeneic Hematopoietic Stem Cell Transplantation (HCT)

This phase I trial studies the side effects and best dose of CD4+ and CD8+ HA-1 T cell receptor (TCR) (HA-1 T TCR) T cells in treating patients with acute leuk…

Acute Biphenotypic LeukemiaAcute Myeloid LeukemiaBlast Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive+11 more

Phase II Study of Cladribine Plus Idarubicin Plus Cytarabine (ARAC) in Patients With AML, HR MDS, or Myeloid Blast Phase of CML

This phase II trial studies how well cladribine, idarubicin, cytarabine, and venetoclax work in patients with acute myeloid leukemia, high-risk myelodysplastic…